OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-52M51 (Anti-Notch1)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--OncoMed Pharmaceuticals advances another anti-cancer stem cell therapy into the clinic and receives a milestone payment from GlaxoSmithKline

See the original post here:

OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-52M51 (Anti-Notch1)

Related Posts

Comments are closed.